1 il 6  (R&D Systems)

Journal: Bone Research

Article Title: Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice

doi: 10.1038/s41413-026-00526-4

Figure Lengend Snippet: DQ reduces caudal disc degeneration and senescence in SM/J mice. a , b Schematic showing study design: intraperitoneal injections of DQ, Nav., or a Vehicle control were administered once every week to mice starting at 4 weeks of age and ending at 17 weeks of age. a’ –a’” SafraninO/Fast Green/Hematoxylin staining evaluated with modified Thompson scoring shows DQ improves disc degeneration in SM/J mice. Images reflect the range of degenerative outcomes across treatment cohorts. b’ –b” Safranin/Fast Green/Hematoxylin staining evaluated with modified Thompson scoring shows Nav. does not improve disc degeneration in SM/J mice. Quantitative immunohistochemistry shows reduced ( c–c” ) p19 (NP and AF) and ( d–d” ) p21 (AF only) in DQ-treated SM/J discs. SASP markers of ( e–e” ) TGF β, ( f–f” ) IL-6, ( g–g” ) MMP13, and ( h–h” ) IL-1β indicate DQ mediates SASP in SM/J discs. Data are shown as mean ± SD. Significance was determined using an unpaired t -test or Mann-Whitney test, as appropriate. Distribution statistics were determined using a χ 2 test. 17 weeks old ( n DQ = 11, 6 females + 5 males; n CT = 13, 6 females + 7 males; n Nav. = 7, n Veh. = 7)

Article Snippet: Tissue sections were then blocked in 2%–10% normal serum in PBS-T, and incubated with antibodies against p19 (1:100, Novus NB200-106), p21 (1:200, Novus NB100-1941), collagen I (1:100, Abcam ab34710), aggrecan (1:50; Millipore; AB1031), chondroitin sulfate (1:300, Abcam ab11570), IL-1b (1:100, Novus NB600-633), IL-6 (1:50, Novus NB600-1131), TGFb (1:100; Abcam; ab92486), collagen X (1:500, Abcam ab58632), CA3 (1:150, Santa Cruz), and GLUT-1 (1:200, Abcam, ab40084).

Techniques: Control, Staining, Modification, Immunohistochemistry, MANN-WHITNEY

Journal: Bone Research

Article Title: Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice

doi: 10.1038/s41413-026-00526-4

Figure Lengend Snippet: JUN pathway inhibition mimics the positive effect of DQ in decreasing senescence and SASP in human degenerated NP cells. a Grade IV and V human degenerated NP cells show a lower percentage of β-Gal-staining after treatment with DQ and JUN inhibitor, or only DQ, respectively. b Grade IV Human NP cells exhibit lower expression of IL-6 , MMP2 , and MMP13 compared to the stimulus group. Additionally, DQ treatment resulted in a decrease in CDKN1A and IL-6 , while T5224 enhanced MMP13 expression. c Grade V human NP cells exhibit lower expression of CDKN1A, CDKN2A, IL-6 , CCL2 , MMP2 , and MMP13 relative to the stimulus group. DQ treatment attenuated the expression of IL-6 and CCL2 , and MMP2 . T5224 ameliorated CDKN1A , IL-6 , CCL2 , and MMP2 expression. Data are shown as mean ± SD. Significance was determined using Dunnett’s multiple comparisons test ( n = 3 independent experiments, performed in triplicate)

Article Snippet: Tissue sections were then blocked in 2%–10% normal serum in PBS-T, and incubated with antibodies against p19 (1:100, Novus NB200-106), p21 (1:200, Novus NB100-1941), collagen I (1:100, Abcam ab34710), aggrecan (1:50; Millipore; AB1031), chondroitin sulfate (1:300, Abcam ab11570), IL-1b (1:100, Novus NB600-633), IL-6 (1:50, Novus NB600-1131), TGFb (1:100; Abcam; ab92486), collagen X (1:500, Abcam ab58632), CA3 (1:150, Santa Cruz), and GLUT-1 (1:200, Abcam, ab40084).

Techniques: Inhibition, Staining, Expressing